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The receptor tyrosine kinase KIT and its ligand, stem cell factor (SCF), are essential for the proliferation and
survival of normal melanocytes. In melanomas arising on mucosal, acral, and chronically sun-damaged skin,
activating KIT mutations have been identified as oncogenic drivers and potent therapeutic targets. Through an
initial whole-genome screen for aberrant promoter methylation in melanoma, we identified the KIT promoter as a
target for hypermethylation in 43/110 melanoma cell lines, and in 3/12 primary and 11/29 metastatic cutaneous
melanomas. Methylation density at the KIT promoter correlated inversely with promoter activity in vitro and
in vivo, and the expression of KIT was restored after treatment with the demethylating agent 5-aza-20-
deoxycytidine. Hypermethylation of KIT showed no direct or inverse correlations with well-documented
melanoma drivers. Growth of melanoma cells in the presence of SCF led to reduced KIT expression and
increased methylation density at the KIT promoter, suggesting that SCF may exert a selection pressure for the loss
of KIT. The frequent loss of KIT in cutaneous melanoma by promoter hypermethylation suggests that distinct KIT
signaling pathways have opposing roles in the pathogenesis of melanoma subtypes.
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INTRODUCTION
The growth, survival, migration, and differentiation of
melanocytes are complex processes that are controlled by
paracrine and autocrine cytokine networks (Imokawa, 2004).
One of the important paracrine growth factors for the
melanocytic lineage is stem cell factor (SCF). During
embryonic development, SCF is critical for the survival and
proliferation of neural crest–derived melanoblasts, and it
serves as guidance cues that direct the migration of these
cells to their final destination in the hair follicle and epidermis
(Lin and Fisher, 2007).
Signal transduction by SCF occurs through KIT, a class III
tyrosine kinase receptor that is expressed on several cell types,
including hematopoietic progenitors, mast cells, melanoblasts,
and differentiated melanocytes (Lennartsson and Ro¨nnstrand,
2012). Ligand binding causes KIT to homodimerize, leading to
the activation of its intrinsic kinase activity through
autophosphorylation of tyrosine residues. KIT has a number
of potential tyrosine phosphorylation sites, which interact with
multiple downstream signaling pathways, including the
phosphatidylinositol 3-kinase, MAP kinase, and Src family
kinase pathways (Lennartsson and Ro¨nnstrand, 2012). One of
the downstream targets of these pathways is the melanocyte
master regulator the microphthalmia transcription factor
(MITF) (Levy et al., 2006). Germline mutations in KIT, SCF,
and MITF are associated with a range of pigmentation
disorders (Lin and Fisher, 2007), highlighting the importance
of the KIT/SCF system and its signaling to MITF in controlling
various cellular activities in the melanocytic system.
A large body of evidence has implicated aberrant KIT
signaling in the development and progression of melanoma.
Several studies based on immunohistochemical evaluation
have shown that KIT is expressed in normal melanocytes and
benign nevi, but it is lost with progression to invasive and
metastatic forms (Montone et al., 1997; Shen et al., 2003; Zhu
and Fitzpatrick, 2006). Consistent with these data, KIT
expression is lost in a great proportion of melanoma-derived
cell lines (Lassam and Bickford, 1992; Natali et al., 1992;
Zakut et al., 1993), and lack of KIT expression correlates with
a higher metastatic potential of melanoma xenografts in nude
mice (Gutman et al., 1994). Furthermore, forced KIT
expression in KIT-deficient melanoma cell lines retards the
growth of these cells in nude mice and confers susceptibility
to SCF-induced growth arrest and apoptosis in vitro (Huang
et al., 1996). Although all of the above observations supported
a tumor-suppressing role of KIT in melanoma, this view has
markedly changed. Most importantly, genome-wide screens
have uncovered KIT amplifications and activating mutations in
a large proportion of melanomas on palms, soles and
subungual sites (acral melanomas), mucosal membranes,
and chronically sun-damaged skin (Curtin et al., 2006). The
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majority of KIT mutations occur in the juxtamembrane region
of the receptor, which is also a target for mutations in 80% of
gastrointestinal stromal tumors and smaller proportions of
some hematological malignancies. These mutations lead to
ligand-independent activation of KIT and its downstream
signaling pathways (Lennartsson and Ro¨nnstrand, 2012),
and they constitute potent therapeutic targets for the
tyrosine kinase inhibitor imatinib mesylate, with clinical
activity observed in patients with metastatic gastrointestinal
stromal tumor (Heinrich et al., 2003) and in patients with
metastatic KIT-mutated extracutaneous melanomas (Guo et al.,
2011; Hodi et al., 2013). Collectively, these later findings have
established KIT as a bona fide oncogene in melanoma.
Research over the past 30 years has identified the main
genetic drivers in cutaneous melanoma (reviewed in Dahl and
Guldberg, 2007; Tsao et al., 2012). In an effort to generate, on
a whole-genome scale, a profile of epigenetic alterations in
cutaneous melanoma, we initially compared promoter
methylation patterns of four well-characterized melanoma
cell lines with that of normal cultured melanocytes. This
analysis led to the identification of KIT as a frequent target for
epigenetic silencing in cutaneous melanoma.
RESULTS
Whole-genome promoter methylation profiling in melanoma cell
lines and cultured melanocytes
Genome-wide promoter methylation profiling was performed
in normal cultured human epidermal melanocytes and four
human melanoma cell lines (ESTDAB-019, ESTDAB-013,
ESTDAB-024, and SK-MEL-28). We used the well-established
methylated DNA immunoprecipitation (MeDIP) approach,
which uses an anti-5-methylcytosine antibody to provide
enrichment of DNA fragments containing 5-methylcytosine
(Weber et al., 2005). The enriched DNA was hybridized to
human promoter microarrays containing 244 k 60-mer probes,
which cover 5.5 kb upstream to 2.5 kb downstream of the
transcription start site of B21,000 defined human RefSeqs.
This approach allows unbiased analysis of gene promoters,
including non-CpG island promoters, which can also be targets
for silencing by DNA methylation in tumorigenesis (Han et al.,
2011). As our focus in this study was on DNA methylation
changes with a potential impact on gene expression, we
restricted our analysis to probes within proximal promoter
regions, defined here as 300 nucleotides upstream and 200
nucleotides downstream of the transcription start site. Owing
to the small sample size, we used M-values as the method for
estimating methylation levels (Du et al., 2010).
When comparing the methylation profile of normal mela-
nocytes with those of melanoma cells, we identified 663
promoter regions that were hypermethylated in at least one of
the four melanoma cell lines and 54 that were hypermethy-
lated in all four cell lines (Supplementary Table S1 online).
Examples of the array-based methylation profiling of these
genes are shown in Figure 1a, illustrating the increased
methylation levels around the transcription start site in
melanoma cells compared with normal melanocytes. To
validate the findings of the MeDIP analysis, we selected four
genes for promoter methylation and gene expression analyses:
DDIT4L, NID1, PPP1R3C, and RRAD. Two of these genes
(DDIT4L and PPP1R3C) have previously been shown to be
aberrantly hypermethylated in melanoma (Furuta et al., 2006;
Koga et al., 2009; Gao et al., 2013). The methylation status of
each promoter was determined using methylation-sensitive
melting-curve analysis (MS-MCA), which measures methy-
lation content as a function of the melting temperature (Tm) of
an amplicon generated from a bisulfite-treated template
(Worm et al., 2001). Analysis of DDIT4L, NID1, PPP1R3C,
and RRAD confirmed the higher methylation levels in all four
melanoma cell lines compared with normal melanocytes
(Figure 1b and data not shown). Quantitative RT-PCR analysis
of the same four genes revealed an inverse correlation between
promoter hypermethylation and gene expression, with higher
expression levels in melanocytes and low to undetectable
expression in the cell lines (Figure 1c).
KIT is frequently hypermethylated and silenced in melanoma cell
lines
The KIT promoter was enriched in the MeDIP approach
(Figure 2a; Supplementary Table S1 online) and was selected
for more in-depth analysis. As shown in Figure 2b, ESTDAB-
019 and SK-MEL-28 had an MS-MCA profile of the KIT
promoter similar to that of the fully methylated control,
melanocytes had a profile corresponding to the unmethylated
control, and ESTDAB-013 and ESTDAB-024 had a composite
profile. Bisulfite pyrosequencing confirmed that the KIT
promoter was densely methylated in ESTDAB-019 and SK-
MEL-28, unmethylated in melanocytes, and intermediately
methylated in ESTDAB-013 and ESTDAB-024 (Figure 2c and
data not shown). Next, using MS-MCA, we determined the
methylation status of the KIT promoter in 106 additional
melanoma cell lines (Supplementary Table S2 online). Over-
all, 43 of the 110 cell lines (39%) showed increased KIT
promoter methylation levels.
Expression of KIT was analyzed in 70 of the 110 melanoma
cell lines using RT-PCR (Supplementary Table S2 online).
Expression of KIT protein at the cell surface was confirmed by
FACS analysis in selected cell lines (Supplementary Figure S1
online). There was a strong correlation between KIT expression
and KIT promoter methylation, with increased methylation
levels in 19 out of 20 cell lines showing loss of KIT expression
(P¼3108; Fisher’s exact test). However, the correlation
was not absolute, as KIT mRNA was detected in 11 out of
50 cell lines with a hypermethylated KIT promoter (22%). To
further characterize the association between methylation
status and transcriptional activity of the KIT promoter, we
determined the methylation density at 34 individual CpG sites
using bisulfite pyrosequencing and measured expression levels
using quantitative RT-PCR in 12 cell lines showing various
MS-MCA profiles of KIT hypermethylation (Figure 2d). As
shown in Figure 2e, KIT was expressed only in those three cell
lines with the lowest KIT promoter methylation density
(ESTDAB-013, EST146, and EST168). Furthermore, KIT expres-
sion was lost in all of the 14 cell lines with fully hypermethy-
lated KIT promoters (Figure 2d and e, and data not shown),
suggesting that methylation density at the KIT promoter is a
main determinant of KIT expression.
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To investigate a causal relationship between KIT promoter
hypermethylation and transcriptional silencing, we treated
four nonexpressing melanoma cell lines with the demethylat-
ing agent 5-aza-20-deoxycytidine. RT-PCR analysis showed
that 5-aza-20-deoxycytidine restored KIT expression in a dose-
dependent manner (Figure 2f and data not shown). Further-
more, FACS analysis showed that KIT was re-expressed at the
cell surface in KIT-negative cells after treatment with 5-aza-20-
deoxycytidine (Supplementary Fig S1b online). Collectively,
these results suggest that KIT promoter hypermethylation is a
frequent cause of transcriptional silencing of KIT in melanoma
cell lines. Loss of the transcription factor AP-2 has been
suggested as a mechanism by which KIT expression is lost
during melanoma progression (Huang et al., 1998). However,
AP-2 was expressed in all of the 27 melanoma cell lines
tested, including 11 lacking KIT expression (data not shown).
KIT hypermethylation in uncultured melanomas
A previous study found KIT promoter hypermethylation in two
rhabdomyosarcoma cell lines, which was considered as an
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Figure 1. Genome-wide screen for aberrant promoter methylation in melanoma cell lines. (a) Plots from the Agilent DNA Analytics software showing the
methylation patterns for the PPP1R3C and NID1 promoters in four melanoma cell lines and normal human melanocytes (HEMn). For each sample, Cy5-labeled
methylation-enriched DNA and Cy3-labeled input genomic DNA were competitively hybridized to an Agilent Human Promoter Array. Each point represents a
probe plotted at its genomic position (hg18 build; x axis) relative to its log2(Cy5/Cy3) (M-value; y axis). The gene is represented by horizontal bars. (b) Analysis of
the methylation status of the PPP1R3C and NID1 promoters by MS-MCA. Bisulfite-treated DNA was amplified in the presence of SYBR Green I, and the melting
characteristics of the PCR products were determined by continuous fluorescence monitoring during a temperature transition. Shown is the negative derivative of
fluorescence over temperature ( dF/dT) versus temperature. Universal methylated DNA (IVM) and whole-genome amplified (WGA) DNA provided positive
controls for methylated and unmethylated alleles, respectively. (c) Expression levels of DDIT4L, NID1, PPP1R3C, and RRAD in melanoma cell lines and normal
melanocytes determined by qRT-PCR and normalized to PBGD expression. Expression in melanocytes was set at 1. The data represent the meanþ SD of three
measurements. MS-MCA, methylation-sensitive melting-curve analysis; qRT-PCR, quantitative RT-PCR.
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in vitro artifact as aberrant KIT methylation was not detected
in uncultured tumor specimens (Enguita-German et al., 2011).
To determine whether KIT promoter hypermethylation in
melanoma cell lines was an in vitro culture phenomenon,
we first took advantage of five frozen tumor biopsies from
which some of our cell lines had been established. In all cases,
cell line and corresponding tumor tissue had similar KIT
promoter MS-MCA profiles. Most important, for the two cell
lines with hypermethylated KIT (ESTDAB-019 and ESTDAB-
023), large fractions of hypermethylated KIT alleles were
detected in the corresponding uncultured specimens
(Figure 3a and Supplementary Table S2 online), demonstrating
that KIT hypermethylation had occurred in vivo.
We next investigated the methylation status of the KIT
promoter region in frozen surgical biopsies from benign nevi
(N¼ 2) and primary (N¼12) and metastatic (N¼ 29) cuta-
neous melanomas using MS-MCA and confirmed the results
for selected samples using bisulfite pyrosequencing
(Figure 3b). KIT promoter hypermethylation was detected in
3 of the primary melanomas (25%) and 11 of the metastatic
melanomas (38%), and in none of the nevi (Supplementary
Table S3 online). Finally, to investigate whether KIT promoter
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Figure 2. Evaluation of the methylation status of the KIT promoter region in melanoma cell lines and normal melanocytes. (a) MeDIP analysis showing the
pattern of CpG methylation at the KIT promoter. See legend to Figure 1a for details. (b) MS-MCA of KIT promoter methylation. (c) Plots from the PyroMark Q24
software showing methylation levels at individual CpG sites (shaded regions) in the KIT promoter determined by bisulfite pyrosequencing. The sequence at the
bottom refers to the nucleotide dispensation, and the y axis represents the intensity of the fluorescent signal. (d) Methylation density at the KIT promoter in
melanoma cell lines and HEMn. The data shown represent the results obtained for 34 CpG sites analyzed by bisulfite pyrosequencing. (e) KIT expression levels in
melanoma cell lines and HEMn determined by qRT-PCR and normalized to PBGD expression. The data represent the meanþ half-range of two measurements.
(f) Re-expression of KIT induced by 5-aza-20-deoxycytidine (5-aza-CdR) in melanoma cells carrying a hypermethylated KIT promoter. HEMn, human melanocytes;
MeDIP, methylated DNA immunoprecipitation; MS-MCA, methylation-sensitive melting-curve analysis.
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hypermethylation correlated with the loss of KIT expression
in vivo, we examined DNA from archived formalin-fixed
paraffin-embedded tissues from 57 primary cutaneous mela-
nomas and compared the results with an immunohistochem-
ical analysis of KIT expression. Overall, KIT promoter
hypermethylation was detected in 19 out of 20 KIT-negative
and 3 out of 37 KIT-positive tumors (P¼4.510 11; Fisher’s
exact test).
Association of KIT promoter hypermethylation with known
melanoma drivers
Molecular cancer drivers often display patterns of mutual
exclusivity across tumors, reflecting their partially redundant
functions as individual components of the same oncogenic
signaling pathways (Vogelstein and Kinzler, 2004). To
investigate whether KIT promoter hypermethylation was
mutually exclusive to known melanoma drivers, we
compared the KIT methylation status in 105 melanoma cell
lines with the status of 15 common genetic (BRAF, NRAS,
TP53, PTEN, INK4A (p16), ARF (p14), CCND1, MYC, CDK4,
and MITF) and epigenetic (APC, IGFBP7, PYCARD, RARB,
and RASSF1A) drivers, which have all been previously charac-
terized in the same series of cell lines (Dahl et al., 2013). KIT
promoter hypermethylation showed direct correlations with
other DNA methylation events, consistent with a CpG island
methylator phenotype (Issa, 2004; Tanemura et al., 2009), but
no statistically significant correlations with any of the genetic
drivers (Supplementary Table S4 online).
Exposure to SCF triggers epigenetic silencing of KIT in
melanoma cells
Previous work has shown that although SCF is required to
support the proliferation and survival of normal melanocytic
cells, it may inhibit the growth of KIT-expressing melanoma
cells (Funasaka et al., 1992; Zakut et al., 1993). Furthermore,
Huang et al. (1996) showed that forced expression of KIT in
the KIT-negative human melanoma cell line A375SM
rendered these cells susceptible to SCF-induced cell-cycle
arrest and apoptosis. To recapitulate these studies, but avoid-
ing the possible confounding effects of KIT overexpression, we
examined the effect of SCF on ESTDAB-013 melanoma cells,
which express high levels of KIT and display a relatively low
density of KIT promoter hypermethylation (Figure 2d and e).
We reasoned that these cells had a propensity to epigeneti-
cally silence KIT when a selection pressure was re-established.
Initial FACS analysis showed that KIT was expressed on the
surface of the vast majority of ESTDAB-013 cells (Figure 4a).
After 3 days of treatment with 200 ng ml 1 SCF, there was no
increase in the number of apoptotic cells, as determined by
flow-cytometric analysis of annexin V levels (data not shown).
However, after being cultured in the presence of SCF for
3 weeks, these cells showed reduced expression of KIT, as
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Figure 3. Evaluation of KIT promoter methylation in uncultured melanomas. (a) MS-MCA of the KIT promoter in the ESTDAB-023 melanoma cell line and
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determined by FACS (Figure 4a) and quantitative RT-PCR
(Figure 4b) analysis, as well as an increase in methylation
density at the KIT promoter (Figure 4c and d). These data
suggest that SCF can induce epigenetic downregulation of KIT
in melanoma cells in vitro.
DISCUSSION
Studies from various research disciplines have demonstrated
an extensive heterogeneity of melanoma at the clinical,
cellular, and molecular levels. Significant progress toward
understanding this heterogeneity has been obtained through
detailed genome-wide studies of somatic, genetic, and epige-
netic alterations, which have uncovered distinct molecular
profiles across melanoma stages and subtypes (Whiteman
et al., 2011; Tsao et al., 2012). One of the notable mole-
cular differences lies within the profile of key driver
oncogenes. Although BRAF and NRAS mutations are present
in the majority of cutaneous and conjunctival melanomas,
mutations in two members of the Gaq family of guanosine
triphosphatases, GNAQ and GNA11, are common and
mutually exclusive in uveal melanomas and blue nevi (Van
Raamsdonk et al., 2010), and KIT mutations are found nearly
exclusively in melanomas arising on mucosal, acral, and
chronically sun-damaged skin (Curtin et al., 2006). The
molecular background for this genetic variation remains
unclear but may be related to differences in the inherent pro-
perties of precursor cells, differences in tissue microenviron-
ment, or both (Whiteman et al., 2011).
Given the well-established function of mutated KIT as a
potent melanoma oncogene, the finding that this receptor is
epigenetically silenced in a large proportion of cutaneous
melanomas was unexpected. Specifically, we found that a
CpG island in the promoter of KIT was hypermethylated in
more than one-third of melanoma cell lines and biopsies.
Furthermore, methylation density at this region correlated
inversely with KIT expression in vitro and in vivo, and KIT
expression could be restored by pharmacological DNA
demethylation. Several mechanisms have been described that
can mediate the downregulation of KIT, including dysregu-
lated expression of specific microRNAs (Felicetti et al., 2008;
Igoucheva and Alexeev, 2009; Siemens et al., 2013) or the AP-
2 transcription factor (Huang et al., 1998), consistent with the
idea that loss of KIT is a consequence rather than a cause of
melanoma progression. The frequent epigenetic silencing of
KIT owing to promoter hypermethylation more directly
implicates the loss of KIT in melanoma pathogenesis, sub-
stantiating previous suggestions that KIT may have a tumor-
suppressive function in cutaneous melanoma. Furthermore,
the strong correlation with transcriptional silencing suggests
that KIT promoter hypermethylation represents the main
mechanism responsible for stably inherited repression of KIT
during melanoma progression.
The well-documented melanoma drivers display clear
patterns of mutual exclusivity according to their functions in
the canonical oncogenic signaling pathways (Dahl et al.,
2013). Epigenetic silencing of KIT did not correlate with any
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of the known genetic melanoma drivers, suggesting that the
tumor-suppressive role of KIT is associated with a hitherto
unknown independent molecular pathway. Furthermore, as
KIT is expressed in large proportions of metastatic melanomas
and melanoma cell lines, it may not have a classical
‘‘gatekeeper’’ function in the context of cutaneous
melanoma. The growth-suppressive function of KIT in some
melanomas should probably best be viewed in the context of
microenvironmental cues and intracellular signaling. Indeed,
growth of KIT-expressing melanoma cells in the presence of
SCF led to reduced KIT expression and increased methylation
density at the KIT promoter, suggesting that SCF imposes a
selection pressure for the loss of KIT. In this respect, our data
support early studies showing that ectopic expression of KIT in
melanoma cells sensitizes these cells to SCF (Huang et al.,
1996).
In the adult skin, production of SCF by keratinocytes,
endothelial cells, and fibroblasts is a main regulator of
melanocyte homeostasis, supporting the recruitment, prolif-
eration, and survival of melanocytes and their precursors
(Grichnik, 2008; White and Zon, 2008). The loss of
requirement for ligand-dependent KIT activation during the
transformation of melanocytic cells may at least in part be
attributed to the redundant pathway activation through genetic
modification, such as mutation of BRAF or NRAS. The
mechanism conferring sensitivity of melanoma cells to SCF
remains unknown, but it may be caused by a synthetic lethal
relationship between SCF-induced and oncogenic signaling. It
is known that growth-factor stimulation may have biphasic
effects, with hyperstimulation of the RAS/MAPK pathway
leading to cell cycle arrest, senescence, or death (Serrano
et al., 1997). Furthermore, as SCF-KIT interaction mediates
melanocyte adhesion to keratinocytes and thereby prevents
melanocyte proliferation (Haass and Herlyn, 2005), there may
be dual selection for melanocytes with an oncogenic mutation
to lose KIT, both to escape from control by keratinocytes and
to avoid overstimulation of the MAPK pathway.
The opposing functions of KIT in melanoma development,
with growth-promoting effects in normal melanocytic cells
and extracutaneous melanomas versus growth-suppressive
effects in cutaneous melanomas, may have therapeutic impli-
cations. The identification of KIT as an oncogenic driver in
extracutaneous melanomas (Curtin et al., 2006) has provided
an important opportunity for targeted therapy of melanoma.
However, clinical KIT inhibitors effectively target wild-type
KIT, as demonstrated by skin hypopigmentation in patients
treated with imatinib (Tsao et al., 2003), and therefore could
contribute to the progression of early-stage melanomas that
are growth-inhibited owing to intrinsic expression of KIT.
Therefore, caution should be taken against the use of KIT
inhibitors for the treatment of melanomas of cutaneous origin
or with unknown KIT status.
MATERIALS AND METHODS
Melanoma cell lines, melanocytes, and reagents
The 110 human melanoma cell lines used in this study (listed in
Supplementary Table S2 online) have been described and character-
ized previously (Guldberg et al., 1997; Worm et al., 2004; Jo¨nsson
et al., 2007; Dahl et al., 2013). The majority of these cell lines
(N¼ 105) were obtained from The European Searchable Tumour Line
Database (ESTDAB) (http://www.ebi.ac.uk/ipd/estdab). SK-MEL-28
cells were purchased from the ATCC. Melanoma cells were
routinely cultured as monolayers in RPMI 1640 medium containing
10% fetal bovine serum and antibiotics at 37 1C and 5% CO2.
Primary human melanocytes (Invitrogen, Carlsbad, CA) were
maintained in Medium 254 containing Human Melanocyte Growth
Supplement 2 (Invitrogen) at 37 1C and 5% CO2. SCF and 5-aza-20-
deoxycytidine were purchased from Sigma-Aldrich (St. Louis, MO).
Pathologic specimens
Fresh-frozen biopsy specimens from benign nevi and melanomas
were obtained from the Department of Pathology, Rigshospitalet,
Copenhagen, Denmark (Worm et al., 2004). The clinicopathological
characteristics of these biopsies are listed in Supplementary Table S3
online. Formalin-fixed, paraffin-embedded sections from primary
melanomas were obtained from the Institute of Pathology, Aarhus
University Hospital, Aarhus, Denmark. All tumor samples were
removed as part of the patient’s treatment, and the study was
approved by the local ethics committees. All tumor samples were
removed as part of the patients’ treatment, and only tissue sections
that were not needed for diagnosis were used in the study. In
accordance with Danish law and approval by the Danish Ethics
Committee, patient consent was not required for the retrospective
analysis of archival tissue biopsies.
DNA isolation and bisulfite treatment
Genomic DNA was isolated using the Qiagen Mini Prep kit (Qiagen
GmbH, Hilden, Germany (cultured cells and fresh-frozen specimens))
or the Qiamp DNA FFPE Tissue Kit (Qiagen GmbH (formalin-fixed,
paraffin-embedded sections)) and quantified using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Bisulfite conversion of DNA was carried out using the EZ DNA
Methylation-Goldt Kit (Zymo Research, Irvine, CA) according to the
manufacturer’s protocol.
MeDIP and microarray analysis
MeDIP assays were performed essentially as described (Weber et al.,
2005). Eight micrograms of genomic DNA extracted from melanoma
cells and cultured epidermal melanocytes were sonicated using a
Bioruptor (Diagenode, Lie`ge, Belgium) to generate 200- to 600-bp
fragments. Fragmented DNA (1.6mg) was used as a reference sample,
whereas the remaining was subjected to immunoprecipitation.
DNA was denatured for 5 minutes at 95 1C and immunoprecipitated
for 4 hours at 4 1C with 10mg of monoclonal mouse antibody against
5-methylcytosine (Clone 33D3; 1 mg ml 1; Eurogentec, Lie`ge,
Belgium) bound to pan-mouse IgG Dynal magnetic beads
(Invitrogen). The efficiency of the MeDIP was evaluated by real-
time quantitative PCR using previously validated targets (Dahl et al.,
2013). Primer sequences are listed in Supplementary Table S5 online.
Real-time quantitative PCR was performed using the Roche Light-
Cycler 2.0 and the FastStart DNA MasterPLUS SYBR Green I Kit
(Roche, Basel, Switzerland). Immunoprecipitated methylated DNA
was labeled with Cy5 fluorophore and the input genomic DNA was
labeled with Cy3 fluorophore (Agilent Technologies, Santa Clara,
CA). Equal amounts of labeled DNA from the enriched and the
reference samples were combined (2.5–4mg each) and hybridized to
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the Human Promoter Array 244K (Agilent Technologies). Arrays were
then washed and scanned with an Agilent DNA microarray scanner.
Data extraction and normalization were performed using the Feature
extraction software, version 9.5.3.1 (Agilent technologies). DNA
analysis was performed using the DNA analytics program (Agilent
technologies), the UCSC database (http://genome.ucsc.edu), and the
Galaxy tool (http://galaxy.psu.edu).
MS-MCA and pyrosequencing
Methylation-specific melting curve analysis (MS-MCA) (Worm et al.,
2001) was performed using the LightCycler 1.1 and 2.0 instruments
(Roche) and the FastStart DNA Master SYBR Green I Kit (Roche).
Pyrosequencing was performed on a PyroMark Q24 platform, using
PyroMark Gold Q24 Reagents (Qiagen, Valencia, CA). Data analysis
was performed with the PyroMark Q24 software. Primer sequences
are listed in Supplementary Table S5 online. Enzymatically methy-
lated DNA (CpGenome Universal Methylated DNA; Millipore,
Billerica, MA) was used as a methylation-positive control. DNA from
peripheral blood leukocytes from a healthy donor and unmethylated
DNA prepared by whole-genome amplification (WGA; GenomePlex,
Sigma-Aldrich) were used as negative controls for methylation.
Reverse transcription PCR and quantitative reverse transcription
PCR
Total RNA was isolated from melanoma cells and melanocytes using
the RNeasy kit (Qiagen) and quantified using a Nanodrop spectro-
photometer (Nanodrop Technologies). cDNA was synthesized from
2mg of RNA using random hexamers, oligo-dT primers, and Super-
script III Reverse Transcriptase (Invitrogen). Conventional PCR was
carried out using a block thermocycler (GeneAmp PCR System 9600;
Perkin-Elmer, Norwalk, CT) and the HotStar Taq DNA Polymerase
(Qiagen). PCR products were analyzed in a 2% agarose gel. Real-time
quantitative PCR was performed using the Roche LightCycler 2.0 and
the FastStart DNA MasterPLUS SYBR Green I Kit (Roche). Primer
sequences are listed in Supplementary Table S5 online.
Immunohistochemistry
Immunohistochemistry was carried out on melanoma tissue micro-
arrays, as described previously (Lade-Keller et al., 2013). The sections
were incubated at room temperature for 30 minutes with a primary
antibody against KIT diluted 1:500 (polyclonal anti CD117 antibody,
Dako, Glostrup, Denmark). Bound primary antibody was visualized
using the Super Sensitive Polymer-HRP IHC kit (BioGenex, Fremont,
CA) and a novared chromogen (Novared, Vector Laboratories,
Petersborough, UK), and slides were counterstained with hematoxylin.
All slides were digitalized using Zeiss Mirax Scan (Zeiss, Birkerd,
Denmark) and evaluated on a computer screen using the Arrayimager
software (Visiopharm, Hrsholm, Denmark). All tissue microarrays
cores from each patient were evaluated together as a single sample.
Positivity was defined as discrete staining with a predominantly
membranous pattern. Internal positive control was basal cells and
keratinocytes in normal epidermis. Negative internal control was
normal keratinocytes in the outer layers of the epidermis. Liver tissue
was used as an external negative control. The percentage of positively
stained tumor cells was scored semiquantitatively and data were
subsequently dichotomized into two groups: the KIT-negative group
(0% tumor cells stained) and the KIT-positive group (40% tumor cells
stained).
FACS analysis
Surface expression of KIT on melanoma cells was determined using
a phycoerythrin-conjugated anti-KIT/CD117 antibody (AC126-PE;
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and an isotype
control antibody (PE Mouse IgG1 k Isotype Control; BD Biosciences,
San Jose, CA). The cell samples were analyzed using an FC500 MPL
Flow Cytometer (Beckman Coulter) and the CXP analytical software
(Beckman Coulter, Brea, CA).
Apoptosis
Apoptosis was measured using the Annexin V-FITC Apoptosis Detec-
tion Kit (BD Biosciences). Cells were harvested and washed twice in
cold phosphate-buffered saline and resuspended in binding buffer.
A total of 5 105 cells were stained with Annexin V-FITC and
propidium iodide. After 30 minutes of incubation, the cell samples
were analyzed using an FC500 MPL Flow Cytometer (Beckman
Coulter).
Database accession
The array data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and are
accessible through the GEO Series accession number GSE53801
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53801).
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